EGFR and non-small cell lung carcinoma: In this large multicenter, real-life observational study, we considered 880 patients with metastatic NSCLC and a PD-L1 expression ≥ 50%, EGFR, and ALK wild-type tumors who were treated with first-line pembrolizumab monotherapy.